<DOC>
	<DOCNO>NCT01194869</DOCNO>
	<brief_summary>The purpose study identify new treatment regimens good response rate find combination cisplatin sorafenib follow paclitaxel sorafenib shrink size breast tumor allow preserve breast . Sorafenib new drug target blood vessel formation may help chemotherapy work well . Additionally , receive chemotherapy surgery , able determine cancer responsive chemotherapy .</brief_summary>
	<brief_title>Preoperative Trial Sorafenib Combination With Cisplatin Followed Paclitaxel Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast carcinoma . Early stage breast cancer ( Stage I ( tumor size ≥ 1cm ) , II IIIA ) . Invasive breast cancer must estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative , human epidermal growth factor receptor 2 ( Her2 ) negative . If breast cancer Her2 2+ immunohistochemistry ( IHC ) , fluorescence situ hybridization ( FISH ) must negative Her2 gene amplification . No evidence disease outside breast chest wall , except ipsilateral axillary lymph node . Patients must measurable disease define palpable lesion diameter ≥ 1cm measurable caliper and/or positive mammogram ultrasound least one dimension ≥ 1cm . Screening mammogram contralateral breast must perform within past 12 month per standard practice guideline . Clip placement require study entry . Baseline measurement indicator lesion must record Patient Registration Form . To valid baseline , measurement clinical exam must make within 14 day mass palpable . If mass palpable , mammogram MRI must do within 14 day . If mass palpable , diagnostic mammogram affect breast MRI must do within 2 month prior study entry . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 14 day study entry . Normal ( great 50 % ) leave ventricular ejection fraction ( LVEF ) multigated acquisition ( MUGA ) scan echocardiography . Signed informed consent . Adequate organ function within 2 week study entry : Absolute neutrophil count ≥ 1000/mm³ , Hgb ≥ 9.0 g/dl platelet count ≥ 100,000/mm³ Total bilirubin ≤ upper limit normal Creatinine ≤ 1.5 mg/dL calculate creatinine clearance ( CrCL ) ≥ 50 mL/min use Cockroft Gault equation Serum glutamic oxaloacetic transaminase ( SGOT ) ( AST ) serum glutamic pyruvic transaminase ( SGPT ) ( ALT ) alkaline phosphatase must within range allow eligibility Patients must ≥ 18 year . International normalized ratio ( INR ) &lt; 1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Patients history breast cancer great 5 year initial diagnosis disease free eligible study . Patients history ductal carcinoma situ ( DCIS ) eligible treat surgery alone . Prior chemotherapy , hormonal therapy , biologic therapy , investigational agent , target therapy radiation therapy current breast cancer . Metastatic disease baseline stag scan . Medical , psychological surgical condition investigator feel might compromise study participation . History previous current malignancy site exception adequately treat carcinoma insitu cervix basal squamous cell carcinoma skin . Patients history malignancy , remain disease free great five year eligible . Evidence grade 2 great sensory and/or peripheral neuropathy . Serious , uncontrolled , concurrent infection ( ) . Major surgery within 4 week start study treatment , without complete recovery . Pregnant lactate woman eligible . Women men childbearing potential use reliable appropriate contraceptive method eligible . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem . Evidence history bleed diathesis coagulopathy . Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C. Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event ≥ Common Toxicity Criteria Adverse Effects ( CTCAE ) Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug . Cardiac disease : congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>